A10BJ01 - Exenatide |
Propably not porphyrinogenic |
PNP |
Rationale
Hormone analogue not eliminated via Cyp metabolism.
Side effects such as nausea, vomiting and diarrhoea may be potentially porphyrinogenic through reduction in carbohydrate intake.
Chemical description
Synthetic Exendin-2, a 39 amino acid peptide present in the saliva of the Gila monster lizard, which is a functional analog of Glucagon-Like Peptide-1.
Therapeutic characteristics
Exenatide is used in type 2 diabetes in combination with other anti-diabetics, when adequate glycaemic control has not been achieved by mono or dual therapy with metformin and a sulfonylurea.
It is administered as a subcutaneous injection.
The pharmacodynamics effects of exenatide, such as incretin-induced pancreatic liberation of insulin and subsequent tissue uptake of glucose, as well an inhibition of glucagon secretion, are theoretically anti-porphyrinogenic.
Side effects such as nausea, vomiting and diarrhoea may be potentially porphyrinogenic through reduction in carbohydrate intake.
Common adverse reactions of exenatide that may be confused with an acute porphyric attack are nausea, vomiting, constipation and abdominal discomfort.
Metabolism and pharmacokinetics
Nonclinical studies suggest that exenatide is predominantly eliminated via glomerular filtration and subsequent proteolytic break down of the peptide.
References
- Scientific articles
- Hurren KM, Pinelli NR. Drug-drug interactions with glucagon-like peptide-1 receptor agonists. Ann Pharmacother. 2012 May; 46(5):710-7. Epub 2012 Apr 17. PMID 22510669. #1134
- Drug reference publications
- DrugBank. Exenatide. #1133
- Drug interaction databases
- Lexicomp Online. Martindale: The Complete Drug Reference. Exenatide. (Last updated: 10.02.12) #1135
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Byetta). #1136
Similar drugs
© NAPOS 2024